AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original) An oncogene polynucleotide derived from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1.

2. (original) The polynucleotide as claimed in Claim 1 wherein the nucleotide sequence encoding the amino acid sequence of SEQ. ID. No.1 is a nucleotide sequence of SEQ. ID. No.2.

3. (original) A recombinant peptide or its salts, comprising an amino acid sequence of SEQ. ID. No.1 or a partial amino acid sequence of the amino acid sequence.

4. (original) A recombinant oncogenic protein comprising an amino acid sequence of SEQ. ID. No.1.

5. (original) A recombinant vector comprising a polynucleotide encoding the recombinant peptide as claimed in Claim 3.

6. (original) A recombinant vector comprising the polynucleotide as claimed in Claim 1 or 2.

7. (original) A transformed cell produced by transforming a host cell using the recombinant vector as claimed in Claim 5.

8. (original) A transformed cell produced by transforming a host cell using the recombinant vector as claimed in Claim 6.

9. (original) A process for producing the recombinant peptide as claimed in Claim 3 or its salts comprising the steps of:

culturing the transformed cell as claimed in Claim 7 to allow the transformed cell to produce the recombinant peptide as claimed in Claim 3; and

collecting the recombinant peptide produced from the culture.

10. (original) A process for producing the recombinant oncogenic protein as claimed in Claim 4 comprising the steps of:

culturing the transformed cell as claimed in Claim 8 to allow the transformed cell to produce the recombinant oncogenic protein as claimed in Claim 4; and

collecting the recombinant oncogenic protein produced from the culture.

11. (original) An antibody which is a specific antibody generated using the recombinant peptide as claimed in Claim 3 as an immunogen.

12. (original) The antibody as claimed in Claim 11, wherein the antibody is reactive to a partial amino acid sequence of 623 to 1185 region of the amino acid sequence of SEQ. ID. No.1.

13. (original) An antibody reagent kit for an antigen-antibody reaction comprising the antibody as claimed in Claim 11, available for detecting an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 or a peptide fragment derived from the oncogenic protein.

14. (original) A diagnosis kit being usable for detection of an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 or a peptide fragment derived from the oncogenic protein by means of an antigen-antibody reaction, comprising the antibody as claimed in Claim 11.

15. (original) An antisense polynucleotide comprising a complementary nucleotide sequence to a partial nucleotide sequence of the nucleotide sequence of SEQ. ID. No.2, which is a DNA fragment having at least a length selected from the region of 15 to 300 bases.

16. (original) A probe hybridization kit available for detecting an mRNA comprising the nucleotide sequence of SEQ. ID. No.2, its partial nucleotide sequence or cDNA prepared by the mRNA, comprising the antisense polynucleotide as claimed in Claim 15 as the DNA probe therein.

17. (original) A diagnosis kit available for detecting expression of mRNA comprising the nucleotide sequence of SEQ. ID. No.2, which is translated into an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1, by means of a probe hybridization method, comprising the antisense polynucleotide as claimed in Claim 15 as the hybridization probe.

18. (currently amended) A primer pair for PCR amplification of cDNA comprising the nucleotide sequence of SEQ. ID. No.2, consisting of paired primers of:

a nucleotide sequence :

5'-TTGGATCCATGACATCCAGATTTGGGAAAACATACAGTAGG-3' **(SEQ ID NO: 8)**; and

a nucleotide sequence :

5'-TTGAATTCCTAGCAATGTTCCAAATATTCAATCACTCTAGA-3' **(SEQ ID NO: 9)**.

19. (currently amended) A primer pair for PCR amplifying a partial chain in cDNA comprising the nucleotide sequence of SEQ. ID. No.2, consisting of paired primers of:

5'-GAATTCATAGGCACAGCGCTGAACTGTGTG-3'; **(SEQ ID NO: 5)** and

5'-TTGAATTCCTAGCAATGTTCCAAATATTCA-3' **(SEQ ID NO: 6)**.

20. (currently amended) A double strand of short-chain interfering RNA capable of inhibiting expression of mRNA comprising the nucleotide sequence of SEQ. ID. No.2 in a cervical cancer cell, wherein the siRNA has a nucleotide sequence: CGGACTACCCTTAGCACAA **(SEQ ID NO: 7)**.

21. (original) A pharmaceutical composition for inhibiting expression of mRNA comprising the nucleotide sequence of SEQ. ID. No.2 in a cervical cancer cell to arrest growth of the carcinoma cell, comprising the double strand of short-chain interfering RNA as claimed in Claim 20.